Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 20/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 19/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822496 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| Fumaric Acid SCHEMBL7830732 | 0.93 | ADRA1A (0.87) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| Fumaric Acid SCHEMBL7830468 | 0.93 | ADRA1A (0.87) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| SCHEMBL7832378 | 0.91 | ADRA1A (1.00) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| Bromide SCHEMBL7834162 | 0.91 | ADRA1A (0.83) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL7832255 | 0.91 | ADRA1A (0.98) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| SCHEMBL6802383 | 0.91 | ADRA1A (1.00) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL7833241 | 0.90 | ADRA1A (0.98) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL7833110 | 0.90 | ADRA1A (0.98) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| SCHEMBL9044556 | 0.90 | ADRA1A (0.83) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023172240-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC (US) | 2023-09-14 | — | — | WO | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | disclosed |
| US-20250041211-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATMENT OF PRESBYOPIA | Eye Hospital, Wenzhou Medical University (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-4489746-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240423970-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2024-12-26 | — | — | US | disclosed |
| US-12102628-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation | 2024-10-01 | — | — | US | disclosed |
| EP-3654964-B1 | COMPOSITION COMPRISING ATROPINE AND A MIOTIC AGENT AND ITS USE IN THE TREATMENT OF MYOPIA | SEINDA PHARMACEUTICAL GUANGZHOU CORP (CN) | 2024-04-24 | — | — | EP | disclosed |
| WO-2023172840-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172240-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230277521-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC | 2023-09-07 | — | — | US | disclosed |
| US-20230062844-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2023-03-02 | — | — | US | disclosed |
| US-11285141-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102628-B2 | Composition and methods for the treatment of myopia | CHRM3, CHRM2, MYOC | ADRA1A 74/4885ADRA1B 63/4885ADRA1D 99/4885 |
| US-11285141-B2 | Composition and methods for the treatment of myopia | CHRM3, CHRM2, MYOC | ADRA1A 74/4885ADRA1B 63/4885ADRA1D 99/4885 |
| US-20230062844-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | CHRM3, CHRM2, MYOC | ADRA1A 74/4885ADRA1B 63/4885ADRA1D 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.